CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Jefferies Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.
Format: Company Presentation and 1x1 Investor Meetings
Presentation: June 8 from 10:00 – 10:25 am ET in Track 2
The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contacts:
Laurence Watts
Gilmartin Group
619-916-7620
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.60 |
| Daily Change: | 0.41 7.90 |
| Daily Volume: | 643,865 |
| Market Cap: | US$203.390M |
August 26, 2025 August 25, 2025 August 21, 2025 August 13, 2025 July 09, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
